Openbookopenbook
Equity
ARS Pharmaceuticals, Inc(SPRY)
USD --+0.00%
Reward66High
Risk32Moderate
📊75%Data
Thin -56% profit margin · Revenue growing 1472% YoY
SPRY
+0.0 · +0.00%
USD · NASDAQ
ARS Pharmaceuticals, Inc | Healthcare
Growth Machine
Market Cap:917.32M
ℹ️
Reward Rating
66
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
32
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SPRY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $28.83.

What is ARS Pharmaceuticals, Inc?

, a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.

SPRY · Verdict

Solid reward · moderate risk

SPRY scores well on balance sheet and growth with no major weaknesses flagged in the model.

Based on 88% data coverage

SPRY · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet93/100

    Current ratio 14.26

  • Growth89/100

    Revenue +153.0% CAGR

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is ARS Pharmaceuticals, Inc?

, a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 917.32M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: High (66)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap917.32M
P/E RatioN/A
Dividend YieldN/A
52 Week High18.9
52 Week Low6.66
Last AnnualDecember
IPO Date12/4/2020
IncorporatedUSA
Shares Outstanding99M
No. of Employees162
IndustryBiotechnology
ExchangeNASDAQ
Beta0.743
CurrencyUSD
Websitears-pharma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.